tetano
Editor, Senior Moderator
Cell Commun Signal
. 2024 Nov 13;22(1):542.
doi: 10.1186/s12964-024-01925-y. The role of epithelial-mesenchymal transition in pulmonary fibrosis: lessons from idiopathic pulmonary fibrosis and COVID-19
Reyhaneh Niayesh-Mehr[SUP] 1 [/SUP], Mojtaba Kalantar[SUP] 2 [/SUP], Giulio Bontempi[SUP] 3 4 [/SUP], Claudia Montaldo[SUP] 4 [/SUP], Saeedeh Ebrahimi[SUP] 5 [/SUP], Abdolamir Allameh[SUP] 1 [/SUP], Ghader Babaei[SUP] 6 [/SUP], Faezeh Seif[SUP] 7 [/SUP], Raffaele Strippoli[SUP] 8 9 [/SUP]
Affiliations
Despite the tremendous advancements in the knowledge of the pathophysiology and clinical aspects of SARS-CoV-2 infection, still many issues remain unanswered, especially in the long-term effects. Mounting evidence suggests that pulmonary fibrosis (PF) is one of the most severe complications associated with COVID-19. Therefore, understanding the molecular mechanisms behind its development is helpful to develop successful therapeutic strategies. Epithelial to mesenchymal transition (EMT) and its cell specific variants endothelial to mesenchymal transition (EndMT) and mesothelial to mesenchymal transition (MMT) are physio-pathologic cellular reprogramming processes induced by several infectious, inflammatory and biomechanical stimuli. Cells undergoing EMT acquire invasive, profibrogenic and proinflammatory activities by secreting several extracellular mediators. Their activity has been implicated in the pathogenesis of PF in a variety of lung disorders, including idiopathic pulmonary fibrosis (IPF) and COVID-19. Aim of this article is to provide an updated survey of the cellular and molecular mechanisms, with emphasis on EMT-related processes, implicated in the genesis of PF in IFP and COVID-19.
Keywords: COVID-19; Endothelial to mesenchymal transition (EndMT); Epithelial to mesenchymal transition (EMT); Idiopathic pulmonary fibrosis (IPF); Mesothelial to mesenchymal transition (MMT); Pulmonary fibrosis (PF).
. 2024 Nov 13;22(1):542.
doi: 10.1186/s12964-024-01925-y. The role of epithelial-mesenchymal transition in pulmonary fibrosis: lessons from idiopathic pulmonary fibrosis and COVID-19
Reyhaneh Niayesh-Mehr[SUP] 1 [/SUP], Mojtaba Kalantar[SUP] 2 [/SUP], Giulio Bontempi[SUP] 3 4 [/SUP], Claudia Montaldo[SUP] 4 [/SUP], Saeedeh Ebrahimi[SUP] 5 [/SUP], Abdolamir Allameh[SUP] 1 [/SUP], Ghader Babaei[SUP] 6 [/SUP], Faezeh Seif[SUP] 7 [/SUP], Raffaele Strippoli[SUP] 8 9 [/SUP]
Affiliations
- PMID: 39538298
- DOI: 10.1186/s12964-024-01925-y
Despite the tremendous advancements in the knowledge of the pathophysiology and clinical aspects of SARS-CoV-2 infection, still many issues remain unanswered, especially in the long-term effects. Mounting evidence suggests that pulmonary fibrosis (PF) is one of the most severe complications associated with COVID-19. Therefore, understanding the molecular mechanisms behind its development is helpful to develop successful therapeutic strategies. Epithelial to mesenchymal transition (EMT) and its cell specific variants endothelial to mesenchymal transition (EndMT) and mesothelial to mesenchymal transition (MMT) are physio-pathologic cellular reprogramming processes induced by several infectious, inflammatory and biomechanical stimuli. Cells undergoing EMT acquire invasive, profibrogenic and proinflammatory activities by secreting several extracellular mediators. Their activity has been implicated in the pathogenesis of PF in a variety of lung disorders, including idiopathic pulmonary fibrosis (IPF) and COVID-19. Aim of this article is to provide an updated survey of the cellular and molecular mechanisms, with emphasis on EMT-related processes, implicated in the genesis of PF in IFP and COVID-19.
Keywords: COVID-19; Endothelial to mesenchymal transition (EndMT); Epithelial to mesenchymal transition (EMT); Idiopathic pulmonary fibrosis (IPF); Mesothelial to mesenchymal transition (MMT); Pulmonary fibrosis (PF).